FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005837632> ?p ?o ?g. }

• W3005837632 abstract "Background: Acquired ESR1 mutations (ESR1MUT) are common resistance mechanisms in estrogen receptor positive (ER+) aBC following aromatase inhibitor (AI) therapy. ESR1MUT can be identified using plasma-based cfDNA testing in patients with progressive aBC and may be cleared (i.e. become undetectable) following response to effective therapeutic interventions. Optimal treatment for ESR1MUTaBC has not been established. We retrospectively examined the impact of various treatments on ESR1MUT detection among patients with aBC undergoing serial cfDNA testing. Methods: The deidentified Guardant Health database was queried for patients with aBC (stage IIIB/IV) with multiple cfDNA samples, at least one of which had an ESR1MUT detected (patients tested between March 2014-March 2019 using a 54-73 gene cfDNA next-generation sequencing panel, Guardant360™). Consecutive sample pairs were identified in which the first sample had ≥1 ESR1MUT and subsequent treatment could be determined from the test request form. For patients receiving combination therapy, each therapy was counted individually (e.g. a patient receiving a CDK4/6 inhibitor and an AI would be counted once for each). Each sample pair was classified as to whether any ESR1MUT persisted in the subsequent cfDNA sample. Additionally, the change in ESR1 variant allele fraction (αVAF) between the first and subsequent sample was calculated for each ESR1MUT identified. We considered ESR1MUT that had lower VAF on the subsequent sample (e.g. a negative αVAF) as evidence of a therapeutic response against ESR1MUT for the purpose of this study. The proportion of sample pairs in which the ESR1MUT was cleared, as well as the proportion of any ESR1MUT with decreased VAF was compared by treatment type using Fisher’s exact test. Results: A total of 262 ESR1 mutations were found in 167 unique sample pairs from 124 aBC patients. The median time between sample collection for each pair was 17 weeks (range: 0.7 - 133 weeks). ESR1MUT were cleared in a minority (30/167, 18%) of sample pairs with an overall minimal change in observed VAF (median αVAF of -0.01). A negative ESR1MUT VAF was observed for more than half of all ESR1MUT in patients receiving certain endocrine therapies, including fulvestrant, tamoxifen, and goserelin, and non-endocrine therapies, including chemotherapy, anti-HER2, and CDK4/6 inhibitors, suggesting these agents may still have some efficacy against ESR1MUT (Table 1). The proportion of sample pairs with ESR1MUT clearance was not significantly different for those on endocrine therapy versus those not on endocrine therapy (16% vs 19%). Similarly, there was no significant difference between these groups when examining the proportion of ESR1MUT with decreased VAF (50% vs 50%). Conclusions: In this exploratory analysis of serial cfDNA testing of ESR1MUTin aBC, some variation was observed in the efficacy of commonly used therapies as measured by the proportion of sample pairs with clearance of ESR1MUT and by the proportion of all ESR1MUT with a decreased VAF. We believe these data may be useful in guiding future analysis into optimal therapy for patients with ESR1MUTaBC. Notably, none of the therapies stood out as having promising efficacy against a large proportion of ESR1MUT subclones suggesting that additional therapeutic options may be needed to effectively target and provide long-term disease control of ESR1MUT aBC. Citation Format: Caroline M. Weipert, Thereasa A. Rich, Rebecca J. Nagy, Sarah Croessmann, Ben H. Park, Joyce O9Shaughnessy, Mohammad Nezami, Massimo Cristofanilli, Aditya Bardia, Richard B. Lanman. Cell-free DNA (cfDNA) analysis of ESR1-mutant advanced breast cancer (aBC): Impact of subsequent therapy on mutation persistence [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-01-06." @default.
• W3005837632 created "2020-02-24" @default.
• W3005837632 creator A5014411546 @default.
• W3005837632 creator A5032987754 @default.
• W3005837632 creator A5034972183 @default.
• W3005837632 creator A5067782212 @default.
• W3005837632 creator A5071432873 @default.
• W3005837632 creator A5074681480 @default.
• W3005837632 creator A5086960130 @default.
• W3005837632 creator A5089051936 @default.
• W3005837632 creator A5089382639 @default.
• W3005837632 creator A5091723009 @default.
• W3005837632 date "2020-02-14" @default.
• W3005837632 modified "2023-10-14" @default.
• W3005837632 title "Abstract P5-01-06: Cell-free DNA (cfDNA) analysis of ESR1-mutant advanced breast cancer (aBC): Impact of subsequent therapy on mutation persistence" @default.
• W3005837632 doi "https://doi.org/10.1158/1538-7445.sabcs19-p5-01-06" @default.
• W3005837632 hasPublicationYear "2020" @default.
• W3005837632 type Work @default.
• W3005837632 sameAs 3005837632 @default.
• W3005837632 citedByCount "0" @default.
• W3005837632 crossrefType "proceedings-article" @default.
• W3005837632 hasAuthorship W3005837632A5014411546 @default.
• W3005837632 hasAuthorship W3005837632A5032987754 @default.
• W3005837632 hasAuthorship W3005837632A5034972183 @default.
• W3005837632 hasAuthorship W3005837632A5067782212 @default.
• W3005837632 hasAuthorship W3005837632A5071432873 @default.
• W3005837632 hasAuthorship W3005837632A5074681480 @default.
• W3005837632 hasAuthorship W3005837632A5086960130 @default.
• W3005837632 hasAuthorship W3005837632A5089051936 @default.
• W3005837632 hasAuthorship W3005837632A5089382639 @default.
• W3005837632 hasAuthorship W3005837632A5091723009 @default.
• W3005837632 hasConcept C121608353 @default.
• W3005837632 hasConcept C126322002 @default.
• W3005837632 hasConcept C126894567 @default.
• W3005837632 hasConcept C138944611 @default.
• W3005837632 hasConcept C143998085 @default.
• W3005837632 hasConcept C172313692 @default.
• W3005837632 hasConcept C530470458 @default.
• W3005837632 hasConcept C71924100 @default.
• W3005837632 hasConcept C84606932 @default.
• W3005837632 hasConceptScore W3005837632C121608353 @default.
• W3005837632 hasConceptScore W3005837632C126322002 @default.
• W3005837632 hasConceptScore W3005837632C126894567 @default.
• W3005837632 hasConceptScore W3005837632C138944611 @default.
• W3005837632 hasConceptScore W3005837632C143998085 @default.
• W3005837632 hasConceptScore W3005837632C172313692 @default.
• W3005837632 hasConceptScore W3005837632C530470458 @default.
• W3005837632 hasConceptScore W3005837632C71924100 @default.
• W3005837632 hasConceptScore W3005837632C84606932 @default.
• W3005837632 hasLocation W30058376321 @default.
• W3005837632 hasOpenAccess W3005837632 @default.
• W3005837632 hasPrimaryLocation W30058376321 @default.
• W3005837632 hasRelatedWork W14228319 @default.
• W3005837632 hasRelatedWork W15265948 @default.
• W3005837632 hasRelatedWork W16162527 @default.
• W3005837632 hasRelatedWork W1651072 @default.
• W3005837632 hasRelatedWork W17538324 @default.
• W3005837632 hasRelatedWork W18725558 @default.
• W3005837632 hasRelatedWork W19163398 @default.
• W3005837632 hasRelatedWork W2422317 @default.
• W3005837632 hasRelatedWork W5387012 @default.
• W3005837632 hasRelatedWork W8409996 @default.
• W3005837632 isParatext "false" @default.
• W3005837632 isRetracted "false" @default.
• W3005837632 magId "3005837632" @default.
• W3005837632 workType "article" @default.